McKesson’s Specialty Pivot Drives Earnings Upgrade as Wholesaler Discount Persists

McKesson’s transformation from a traditional drug distributor into a diversified healthcare services and technology platform is accelerating, with oncology, biopharma services, and infusion therapy now powering a disproportionate share of profits. The shift is evident in the company’s fiscal second-quarter results, which prompted management to raise adjusted earnings guidance for fiscal 2027 to $45.60–$46.40 per share, implying 17% to 19% growth.

Although the legacy North American pharmaceutical segment still generates 82% of revenue, it contributed only 52% of adjusted segment operating profit in the quarter. By contrast, the oncology and multispecialty unit (13.5% of revenue) delivered 21.4% of segment profit at a 2.85% margin, while prescription technology solutions (1.4% of revenue) produced 15.4% of segment profit at a 20.2% margin. Underlying oncology profit growth reached 23% excluding prior-year gains, and technology solutions expanded margins by 123 basis points.

Strategic portfolio moves are reinforcing the transition. McKesson completed the Precision Medicine Group acquisition in early November, adding clinical research and commercialization capabilities expected to contribute $1.60–$1.80 per share by year three. A $1.4 billion agreement for a 49% stake in Option Care Health, the largest independent home-infusion provider, is slated to close in the first half of calendar 2027. Meanwhile, the Medical-Surgical business will be spun off as Wellverse via an IPO in the second half of 2027, and a distribution agreement in principle with CVS Health through June 2032 would remove a key customer overhang.

Free cash flow surged 131% year-over-year in the first half to $2.6 billion, with full-year guidance of $4.5–$4.9 billion supporting $5 billion in share repurchases and a 15% dividend increase. The company trades at roughly 23 times the midpoint of raised guidance, below its five-year median of 25.3 times, even as the business mix shifts toward higher-growth, higher-margin specialty services.

Risks include regulatory pressure on 340B and Medicare Part D economics, opioid-related liabilities, execution risk around portfolio changes, and normalization of GLP-1 distribution volumes. Yet with broadening earnings momentum, a discounted valuation relative to historical norms, and multiple catalysts ahead, McKesson’s evolution suggests the market may still be underestimating the durability of its earnings power.

Source link